Story perspectives
FDA Rejects PTC's Vatiquinone; Shares Rise 8%
8/20/2025
48 3
1 of 1
Story summary
- The FDA rejected PTC Therapeutics' vatiquinone for Friedreich's ataxia due to inadequate efficacy evidence.
- Analysts expected the rejection, leading to an 8% increase in PTC's shares.
- PTC intends to consult with the FDA regarding future steps.
- Biogen's Skyclarys remains the sole approved treatment for this condition.
